Press Releases CEL-SCI Corporation

Equities

CVM

US1508376076

Market Closed - Nyse Other stock markets 04:00:00 2024-07-15 pm EDT			5-day change	1st Jan Change
1.31 ^USD	+2.34%		+6.50%	-51.84%

Jul. 08	Cel-Sci Appoints Robert Watson Board's Chair	MT
Jul. 08	CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CEL-SCI Appoints Robert Watson as Chairperson of the Board	Jul. 08	BU
CEL-SCI Presents Head and Neck Cancer Data at Iddst Annual Congress in Budapest, Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	Jun. 19	AQ
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	Jun. 18	BU
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor	Jun. 06	BU
Cel-Sci: Fiscal Q2 Earnings Snapshot	May. 16	AQ
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results	May. 16	BU
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer	May. 09	AQ
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	May. 08	BU
CEL-SCI Appoints Mario Gobbo to Its Board of Directors	Apr. 23	BU
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology	Mar. 19	BU
CEL-SCI Corporation Issues Letter to Shareholders	Mar. 06	BU
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results	Feb. 15	BU
Cel-Sci: Fiscal Q1 Earnings Snapshot	Feb. 14	AQ
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock	Feb. 13	BU
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	Feb. 12	AQ
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	Feb. 09	BU
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head and Neck Cancer Drug	Feb. 07	AQ
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	Feb. 06	BU
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path towards Marketing Authorization for Multikine	Feb. 01	AQ
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®	Jan. 31	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CEL-SCI Corporation

Equities

CVM

US1508376076

Press Releases

Filters